Cemorop axis a ns ercuOs is

Benefits of Isoniazid Chemoprophylaxis Isoniazid has been tested in more than a dozen prospective, randomized, placebo-controlled trials involving more than 100,000 people. These trials have been conducted for several populations including household contacts, tuberculin skin test converters, infected persons with stable radiographic lesions and negative bacteriologic examinations and child and adolescent skin-test reactors. Twelve months of taking isoniazid daily confers 70% to 90% protection against future tuberculosis; six months of therapy provides 50% to 60% protection. This protection has lasted 20 years and is likely to last a lifetime. Preventive therapy with isoniazid is practical because both screening for the infected state and treatment with isoniazid are efficacious, inexpensive and safe. Screening for tuberculous infection is done by the tuberculin skin test.

[1]  B. Woods,et al.  Isoniazid-related hepatitis. , 1997, Digestive diseases.

[2]  E. MacLaughlin,et al.  Treatment of tuberculosis and other mycobacterial diseases. , 1984, The American review of respiratory disease.

[3]  D. Snider,et al.  Treatment of tuberculosis during pregnancy. , 1981, The American review of respiratory disease.

[4]  D. Snider.  Pyridoxine supplementation during isoniazid therapy. , 1980, Tubercle.

[5]  D. Snider,et al.  Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study. , 1978, The American review of respiratory disease.

[6]  G. Comstock,et al.  The competing risks of tuberculosis and hepatitis for adult tuberculin reactors. , 2015, The American review of respiratory disease.

[7]  D. T. Carr.  The tuberculin skin test. , 1972, The American review of respiratory disease.

[8]  S. Ferebee.  Controlled chemoprophylaxis trials in tuberculosis. A general review. , 1970, Bibliotheca tuberculosea.